Spain Diabetes Drugs Market Analysis Report [2022-30]

Spain Diabetes Drugs Market Analysis

$ 3999

The Spain diabetes drugs market size was valued at $1.19 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030 and will reach $1.77 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Spain diabetes drug market will grow as the Spanish government has implemented several initiatives to improve diabetes care, including investing in diabetes education programs and supporting research into new treatments. The key market players are Almirall (ESP), Esteve (ESP), Laboratorios Rovi (ESP), Cinfa Biotech (ESP), Boehringer Ingelheim, and others.

ID: IN10ESPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Chandani Patel

Buy Now

Spain Diabetes Drugs Market Executive Summary

The Spain diabetes drugs market size was valued at $1.19 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030 and will reach $1.77 Bn in 2030. Spain has a mixed economy with a strong focus on the service sector, including healthcare. In 2020, Spain had a gross domestic product (GDP) of approximately 1.2 trillion USD, making it the 13th largest economy in the world. Spain has a universal healthcare system, which is largely funded by the government. In 2019, total healthcare spending in Spain was approximately 10.2% of the country's GDP, which is above the average for European Union countries.

The Spanish healthcare system is financed through a combination of taxes and social security contributions. The system is decentralized, with responsibility for healthcare provision shared between the central government and the autonomous regions. The central government sets national health policies, while the regional governments are responsible for managing healthcare services within their territories.

Spain is one of the countries with a high prevalence of diabetes. According to the International Diabetes Federation, in 2021, there were an estimated 3.7 Mn people living with diabetes in Spain, which represents approximately 8% of the adult population. The incidence of diabetes in Spain is expected to increase in the coming years, driven by factors such as aging population, sedentary lifestyle, and unhealthy diets. The diabetes market in Spain is significant and growing, with a range of medications and devices available to manage the disease. The market includes products such as insulin, oral hypoglycemic agents, GLP-1 receptor agonists, and devices such as glucose monitoring systems and insulin pumps. The Spanish government has taken steps to improve diabetes care in the country, including investing in diabetes education programs and supporting research into new treatments.

The diabetes market in Spain is expected to continue to grow in the coming years, driven by factors such as the aging population and increasing awareness of the disease. However, manufacturers will need to navigate the challenges posed by budget constraints and increasing competition to succeed in the market.

spain diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

Increasing prevalence of diabetes: The prevalence of diabetes in Spain is high and continues to grow. According to the International Diabetes Federation, the number of people with diabetes in Spain is expected to reach 4.4 Mn by 2045.
Growing demand for diabetes treatments: The increasing prevalence of diabetes has led to a growing demand for diabetes treatments, including medications and devices.
Government initiatives to improve diabetes care: The Spanish government has implemented several initiatives to improve diabetes care, including investing in diabetes education programs and supporting research into new treatments.
Advancements in diabetes treatment technologies: Advancements in diabetes treatment technologies, including glucose monitoring systems and insulin pumps, are driving growth in the market.

Market Restraints

Budgetary constraints: Like many countries, Spain faces budgetary constraints in its healthcare system, which have led to restrictions on the use of certain diabetes medications and devices.
Increasing use of generic drugs: The increasing use of generic drugs has put pressure on prices and profit margins for manufacturers.
Reimbursement challenges: Reimbursement challenges, including delays in reimbursement and restrictions on the use of certain medications, have also impacted the market.

Competitive Landscape

Key Players

Almirall (ESP)
Esteve (ESP)
Laboratorios Rovi (ESP)
Cinfa Biotech (ESP)
Boehringer Ingelheim
Sanofi
Boehringer Ingelheim
Eli Lilly and Company
AstraZeneca
Johnson & Johnson
Bayer Pharmaceuticals
Novo Nordisk
Merck
Novartis
GlaxoSmithKline

Notable deals

In 2021, one notable transaction in the Spanish diabetes drugs market was the acquisition of Biomar Microbial Technologies, a Spanish biotechnology company focused on developing treatments for metabolic diseases, including diabetes, by the multinational healthcare company Novo Nordisk. This acquisition is part of Novo Nordisk's ongoing efforts to expand its portfolio of treatments for diabetes and related metabolic disorders.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

In Spain, diabetes drugs are regulated by the Spanish Agency of Medicines and Medical Devices (AEMPS), which is responsible for ensuring that all medications marketed in the country are safe, effective, and of high quality. The AEMPS requires that all diabetes drugs undergo rigorous clinical trials to demonstrate their safety and efficacy before they can be approved for use. Once approved, the AEMPS continues to monitor these drugs to ensure that they remain safe and effective for patients. In addition, the AEMPS also sets guidelines for the prescription, dispensation, and use of diabetes drugs. These guidelines help to ensure that diabetes medications are used appropriately and in accordance with best practices for diabetes care.

One important aspect of diabetes drug regulation in Spain is the requirement for pharmaceutical companies to provide information to patients and healthcare providers about the risks and benefits of these drugs. This information is typically provided in the form of package inserts or patient information leaflets, which outline important safety information and usage guidelines for each medication. The AEMPS plays a critical role in regulating the diabetes drugs market in Spain, helping to ensure that patients have access to safe, effective, and high-quality medications for the treatment of diabetes.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
  - Exenatide (Byetta)
  - Dulaglutide (Trulicity)
  - Semaglutide (Ozempic, Wegovy)
  - Liraglutide (`Saxenda, Victoza)
  - Lixisenatide (Adlyxin)
  - Pramlintide (Symlin)
  - Tirzepatide (Mounjaro)
  - Albiglutide (Tanzeum)
Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.